July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Effect of lid margin debridement on MGD and inflammatory marker MMP-9
Author Affiliations & Notes
  • Charles G Connor
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Srihari Narayanan
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Sandra Fortenberry
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Narges Kasraie
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Karim Sayani
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Eliana Pelfrey
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • William L Miller
    Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, Texas, United States
  • Footnotes
    Commercial Relationships   Charles Connor, None; Srihari Narayanan, None; Sandra Fortenberry, None; Narges Kasraie, None; Karim Sayani, None; Eliana Pelfrey, None; William Miller, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6730. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charles G Connor, Srihari Narayanan, Sandra Fortenberry, Narges Kasraie, Karim Sayani, Eliana Pelfrey, William L Miller; Effect of lid margin debridement on MGD and inflammatory marker MMP-9. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6730.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Meibomian Gland Disease (MGD) is a common cause of evaporative dry eye. Office-based management options for MGD offer better success than home-based options. Korb demonstrated relief in MGD signs and symptoms using debridement-scaling. We showed (ARVO 2015, 2017) that lid margin debridement improves MGD signs and symptoms and decrease ocular surface inflammatory marker MMP-9. The LidPro allows lid debridement without using a surgical instrument. The InflammaDry recognizes elevated levels of MMP-9. The purpose of this study is to determine if MGD signs and symptoms and MMP-9 levels change following lid margin debridement with the LidPro.

Methods : Twenty five MGD patients (6 male,19 female) with evaporative dry eye (Age range 22 to 66 years; mean age 30.68+/- 12.3 years) participated in this study. The OSDI, Non invasive tear break-up time (NITBUT), Meibography grading and Inflammadry test were done just prior to LidPro treatment. All tests were repeated two weeks post-treatment. Data was analyzed by a t-test with post hoc test for significance.

Results : Subjects reported an improvement of ocular surface comfort for an average of 5.4 days +/- 5.03 days after LidPro treatment. At two weeks following treatment, though the OSDI scores decreased from baseline (30.92 +/- 20.62 to 23.69 +/- 18.54) and the NITBUT increased (6.81 +/- 2.7 seconds to 7.06 +/-2.59 seconds), these were not statistically significant. Meibography (Pult grading scheme; Oculus 5M Keratograph) did change significantly (pre-treatment Grade 1.91 to grade 1.20 post-treatment p=0.01). The MGD Efron grading improved from 1.9 to 1.44 p=0.01. While 19 subjects were MMP-9 positive pre-treatment, only 4 became negative at post-treatment.

Conclusions : Lid margin debridement with LidPro resulted in a very short-term benefit to ocular surface comfort as well as improvement in signs such as Meibography grades and MGD Efron grading scores. MMP-9 marker was negative post-treatment in very few patients. The lack of use of a cleaning agent with the LidPro may have decreased the efficacy of the technique. Based on our previous data (ARVO 2015, 2017), other methods of lid margin debridement offer longer term benefits.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×